AUTL logo

AUTLAutolus Therapeutics Ltd - ADR

$1.56
$0.08
(5.41%)
Today
Closed $1.56
$0.01
(0.64%)
After Hours
Updated: 07:58 PM EDT
Reported EarningsMay 14
Mkt Cap$415.2M
Vol923,485.00
23

Extremely Bearish Sentiment

How do you feel about AUTL?

News
all
press releases
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUTL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks
News Placeholder
More News
News Placeholder
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks
News Placeholder
Autolus Therapeutics Q1 Earnings Call Highlights
Autolus Therapeutics Q1 Earnings Call Highlights...
Yahoo! Finance: News
News Placeholder
HC Wainwright Has Negative Outlook for AUTL Q2 Earnings
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2026 earnings estimates for shares of Autolus Therapeutics in a note issued to investors on Thursday, April 30th. HC Wainwright analyst E. Bodnar now anticipates that the company wil...
MarketBeat
News Placeholder
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the company...
MarketBeat
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Upgraded by Jefferies Financial Group
Jefferies Financial Group raised Autolus Therapeutics to a "strong-buy" rating in a report on Monday...
MarketBeat
News Placeholder
Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin Turnaround
Autolus Therapeutics (NASDAQ:AUTL) is seeking to differentiate itself in the CAR-T market by pairing strong clinical activity with a safety profile that could allow broader patient access, CEO...
MarketBeat
News Placeholder
HC Wainwright Issues Positive Outlook for AUTL Earnings
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Equities research analysts at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of Autolus Therapeutics...
MarketBeat
News Placeholder
Needham & Company LLC Reaffirms Buy Rating for Autolus Therapeutics (NASDAQ:AUTL)
Needham & Company LLC restated a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday...
MarketBeat
News Placeholder
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data
Autolus Therapeutics (NASDAQ:AUTL) hosted an investor event focused on its acute lymphoblastic leukemia (ALL) program, featuring clinicians and investigators who discussed the treatment landscape...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.